SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Damiano, J. S. Articles by Dalton, W. S. Search for Related Content PubMed PubMed Citation Articles by Damiano, J. S. Articles by Dalton, W. S. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 93 No. 5 (March 1), 1999: pp. 1658-1667 Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines By Jason S. Damiano, Anne E. Cress, Lori A. Hazlehurst, Alexander A. Shtil, and William S. Dalton From the H. Lee. Moffitt Cancer Center, University of South Florida, Tampa, FL; and the Arizona Cancer Center, University of Arizona, Tucson, AZ.     ABSTRACT Top Abstract Introduction References Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (41) and VLA-5 (51) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in 4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and 4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression. © 1999 by The American Society of Hematology.     INTRODUCTION Top Abstract Introduction References MULTIPLE MYELOMA is an incurable malignancy of the plasma cell characterized by migration and localization to the bone marrow where cells then disseminate and facilitate the formation of bone lesions. Despite initial responses to chemotherapy, myeloma patients ultimately develop drug resistance and become unresponsive to a wide spectrum of anti-cancer agents, a phenomenon known as multidrug resistance (MDR). The development of resistance to front-line chemotherapeutic drugs, such as melphalan (an alkylating agent) and doxorubicin (an anthracycline), is a major factor responsible for treatment failure. P-glycoprotein-mediated drug resistance has been well characterized in hematologic malignancies1,2; however, this mechanism alone cannot account for all drug resistance found in vivo or in vitro, nor is it likely to explain cell survival following initial cytotoxic drug exposure. Non-P-glycoprotein mechanisms conferring low level drug resistance are believed to play important roles in the survival and expansion of the malignant cell population. Factors that allow for tumor cell survival following initial drug exposure need to be identified because these factors may eventually allow for expression of genes associated with acquired drug resistance. For this reason, we investigated the role of a novel, cell adhesion mediated drug resistance (CAM-DR) mechanism that suppresses drug-induced apoptosis and may allow for the eventual emergence of other well characterized mediators of drug resistance such as P-glycoprotein. It has long been known that intercellular interactions may contribute to tumor cell survival during exposure to cytotoxic stresses such as radiation, as was first described by Durand and Sutherland.3 It is also well documented that certain resistance mechanisms may only be functional in vivo, where tumor cells continue to interact with environmental factors such as extracellular matrix (ECM) and cellular counter-receptors. Teicher et al showed that mammary tumors made resistant to alkylating agents in vivo were sensitized to cytotoxic drugs once removed from the animal.4 Most mechanisms of drug resistance that have been discovered were examined in vitro where tumor cell-environmental interactions are not fully appreciated. Within the last 5 years, it has been realized that cell-cell or cell-ECM adhesion can regulate apoptosis and cell survival in a wide variety of cell types.5-7 Adhesive interactions between same cell types have been shown to confer resistance to alkylating agents via alterations in cyclin dependant kinase inhibitors such as p27kip1 although the cell surface molecules mediating this type of kinetic resistance have yet to be identified.8 In addition, adhesion to ECM has been reported to induce P-glycoprotein expression and confer doxorubicin resistance in rat hepatocytes.9 The integrin family of cellular adhesion molecules is a major class of receptors through which cells interact with extracellular matrix components (ECM) and recent evidence has implicated the integrins as being closely involved in the pathology of many diseases.10-12 Integrins have been shown to participate in intracellular signal transduction pathways that may contribute to tumor cell growth and survival, although many of their functions have yet to be characterized in myeloma. Experimental evidence has implicated the 1 integrins and FN as playing a part in apoptotic suppression and cell survival.13-16 Zhang et al14 demonstrated that FN adhesion through 51 (VLA-5) prevented cells from undergoing serum-starvation induced apoptosis by upregulating Bcl-2. Similar observations were made by Scott et al15 and Rozzo et al,16 who found that anti-1 antibodies and antisense oligonucleotides, respectively, enhanced chromatin condensation and nucleosomal DNA laddering, characteristics of cells committed to apoptosis. 1 integrin activation through interactions with ECM components such as FN has also been shown to directly decrease DNA strand breaks in tumor-derived endothelial cells exposed to a number of DNA damaging agents, including etoposide and ionizing radiation.17,18 The 41 (Very Late Activation Antigen 4, or VLA-4), 51 (VLA-5), and 47 heterodimers are the major FN receptors of the integrin family.12,19 Although VLA-5 and 47 expression seem to be variable in most B cells during malignancy, VLA-4 is strongly expressed in myeloma cells collected from bone marrow.20,21 VLA-4 is unique among the integrins as it is the only heterodimer to have conclusively been shown to mediate cell-ECM as well as cell-cell interactions.22 VLA-4 binds to the CS-1 region of FN as well as to vascular cell adhesion molecule-1 (VCAM-1) via separate binding sites.23 Adhesion to FN via VLA-4 has been shown to prolong eosinophil survival and to downregulate FAS antigen expression, leading to a decrease in cell death.24,13 In early hematopoietic and germinal center B cells, adhesion to FN or VCAM-1 via VLA-4 suppresses the apoptotic pathway and contributes to positive selection, an observation that may have relevance to apoptosis-inducing DNA damaging agents targeted at malignant B cells.25,26 Whether any of these adhesion-related resistance mechanisms play a role in myeloma cell survival has yet to be demonstrated; however, longer survival times were obtained when mice injected with a number of tumors, including B lymphoma cells, were treated with a combination of anti-FN-adhesion agents and anticancer drugs.27 As myeloma cells adhere in the bone marrow, they stimulate their own growth and cause osteoclast formation through the increased synthesis and secretion of cytokines such as IL-1, TNF-, M-CSF, and IL-6.28,29 IL-6, a potent growth factor for myeloma cells, is secreted from both tumor and stromal cells in response to co-adhesion and VLA-4 ligation.30 VLA-4 has recently been shown to associate with or cause the phosphorylation of a number of signal transduction molecules including CD19 receptor-associated protein tyrosine kinases and focal adhesion kinase (pp125FAK, or FAK), which is an upstream activator of mitogen activated protien kinase (MAPK), among other proteins.31-34 FAK is now known to play a major role in suppressing apoptosis both in adherent and suspension cells, and its cleavage by caspases early in the apoptotic process further emphasizes its importance within the cell.35-37 Given the evidence that FN adhesion and integrin engagement enhances cell survival in many cases, we examined the relationship between expression and function of the major integrin fibronectin receptors and response to cytotoxic drugs in the human myeloma derived cell line RPMI 8226. Drug-resistant variants were used to examine changes in integrin expression and function following chronic drug exposure, while the drug-sensitive parent line was used to assess the effects of FN on acute drug response.     MATERIALS AND METHODS Cell and culture conditions.   The RPMI 8226 human myeloma cell line (8226/S) was obtained from the American Type Culture Collection (Rockville, MD). The drug resistant cell lines, 8226/DOX6 and 8226/LR5, were selected from 8226/S using step-wise increases of doxorubicin and melphalan, respectively, as described previously.38,39 All cells were grown in suspension in RPMI 1640 medium supplemented with 5% fetal bovine-serum, 1% (vol/vol) penicillin (100 U/mL), streptomycin (100 U/mL), and 1% (vol/vol) L-glutamine (all from GIBCO-BRL, Grand Island, NY). Cells were maintained at 37°C in 5% CO2-95% air atmosphere and subcultured every 6 days. Drugs.   Melphalan (L-phenylalanine nitrogen mustard, LPAM) was obtained from Sigma-Aldrich (St Louis, MO) and was dissolved in acidified ethanol. Doxorubicin was obtained from Sigma-Aldrich and dissolved in sterile ddH2O. Cytotoxicity assays.   96-Well immunosorp plates (Nunc, Denmark) were coated with 50 µL (40 µg/mL) FN (GIBCO) or bovine serum albumin (BSA) overnight and 1% BSA was used to block nonspecific binding sites in the wells for 1 hour before the experiment. Wells were washed with serum-free RPMI 1640 and aspirated. 8226/S cells were washed once and resuspended in serum-free RPMI 1640; then 4 × 104 cells per well (FN coated) or 8 × 103 cells per well (BSA coated) were added to each plate. Cells were incubated for 1 hour at 37°C and 5% CO2, washed with serum free media twice, and were put back into serum-containing media. Following 24 hours in a tissue culture incubator, 20 µL of diluted drug or vehicle control was added to each well for 1 hour, after which media was removed and replaced by drug-free media. Following a 96-hour incubation, 50 µL MTT dye (Sigma) was added to each well for 4 hours. Plates were then centrifuged and each well aspirated. Dye was solubilized with 100 µL DMSO and plates were read at 540 nm on an automated microtiter plate reader. A blank well containing only media and drug was also run as a control in all experiments. IC50 values were calculated by linear regression of percent survival versus drug concentration. Annexin V apoptotic analysis.   Cells, 1 × 106, were attached to FN-coated 6-well plates (Biosource, Camarillo, CA) for 1 hour in serum-free media and nonadhered cells were removed with two washes. Fresh media with serum was added to the plates, which were incubated for 24 hours; 1 × 106 cells were also added to uncoated 6-well plates (Boeringer-Mannheim, Indianapolis, IN). Cells were exposed to 1 µmol/L doxorubcin for 1 hour (plus a 24-hour drug-free incubation period) or 50 µmol/L LPAM for 24 hours. Cells were then collected with 5 mmol/L EDTA/PBS and washed. Phycoerythrin (PE)- or fluorescein isothiocyanate (FITC)-conjugated Annexin V (Clontech, Palo Alto, CA) was then added to 1 × 105 cells and 5,000 to 10,000 events were analyzed on a FACScan machine (Becton Dickinson). RNA collection and cDNA synthesis from FN-adhered myeloma cells.   Cells, 1 × 106, were attached to FN coated 6-well plates as previously described. Total cellular RNA was collected on 3 separate days using TRIzol reagent (GIBCO). RNA was quantitated on a spectophotometer at 260 nm and 1 µg was DNAse treated and requantitated. A single large scale cDNA reaction was prepared for each sample for use in PCR reactions. A 40 µL reverse transcription reaction containing 200 ng RNA, 1 × PCR buffer (10 mmol/L Tris, pH 8.3-50 mmol/L MKCL-1.5 mmol/L MgCl2), 1 mmol/L concentrations each of dATP, dGTP, dCTP, and dTTP; 200 pmol random hexamers, 40 U RNAse inhibitor, and 12 U avian megalovirus reverse transcriptase (Boeringer-Mannheim) was prepared on ice then incubated at 42°C for 1 hour, 99°C for 10 minutes, and quick chilled to 4°C. RNase protection assay.   Twenty micrograms of RNA was isolated from 8226/S cells grown in suspension or adhered to FN using TRIzol reagent and resuspended in hybridization buffer. Bcl-2 family specific probes were synthesized using a template set from Riboquant (San Diego, CA) and labeled using [-32P]UTP and T7 polymerase. Probes were then column purified, quantitated on a scintillation counter, and 5 × 105 cmp was added to each sample. The hybridization reaction was carried out overnight at 56°C. Samples were then RNase treated for 45 minutes at 30°C, hybridized probes were extracted with chloroform:isoamyl alcohol and precipitated using 100% ethanol. Samples were then electrophoresed on a 5% polyacrylamide gel (7 mmol/L Urea), dried down, exposed to film, and analyzed by densitometry software (ImageQuaNT, Molecular Dynamics, Inc, Sunnyvale, CA). Unhybridized probes were used as size standards for each gene analyzed. Expression of Bcl-2, Bcl-Xl, Bcl-Xs, BAX, Bik, Bad, Bcl-w, Bak, Mcl-1, and Bfl1 were quantitated by normalizing to GAPDH and L32 expression. RT-PCR analysis of BCL-2 family gene and drug transporter expression.   BCL-2 amplification was performed essentially as described previously.40 Briefly, 20 µL of PCR reaction mixture (1X PCR buffer, 50 pmol of BCL-2 specific amplimers, 0.25 U Taq polymerase [Boehringer-Mannheim], 1.25 µci [-32P]-dCTP) was added to 5 µL cDNA, followed by incubation at 94°C for 5 minutes and then 26 cycles of 94°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 5 minutes in a thermal cycler (Perkin-Elmer Cetus). Histone 3.3 was amplified as described and used as a control for RNA integrity and quantity.41 Bcl-Xl and -Xs were amplified essentially as described previously, using 26 cycles of PCR.42 The 258 base pair BAX amplicon was amplified using the following primers (Biosynthesis, Lewisville, TX) and conditions: BAX-upstream (5'-ACCAAGAAGCTGAGCGAGTGTCTC-3'), BAX-downstream (5'-CAATGTCCAGCCCATGATGG-3'), cDNA denaturation for 1 minute at 94°C, annealing for 15 seconds at 60°C, primer extension for 15 seconds at 72°C, with a final extension for 5 minutes. All samples were loaded on a 5% nondenaturing polyacrylamide gel and electrophoresed for 2 hours at 80V. For determination of incorporated radionucleotide, gels were dried down and exposed to a phosphorimaging plate (Molecular Dynamics, Inc) overnight. Plates were then scanned on the STORM phosphorimager (Molecular Dynamics) and band intensities (pixels/unit area) for Bcl-2, Bcl-Xl, Bcl-Xs, and BAX were analyzed using ImageQuaNT software and normalized to Histone 3.3 expression. PCR amplification of the MDR1, MRP, and LRP genes was performed essentially as described,41,43,44 using the housekeeping genes histone 3.3 (MDR1) or -actin (MRP and LRP) as internal standards. cDNA synthesized from 8226/DOX6 RNA was used as a positive control for MDR1 PCR. For all reactions, optimal cycle numbers were used and were within the exponential range of PCR amplification as determined by previous experiments.41,43,44 Intracellular drug accumulation assay.   Cells, 0.5 × 106, were adhered to FN-coated 6-well plates for 24 hours, as described previously. Control wells were coated with BSA or were uncoated. RPMI 1640 containing doxorubicin was added to each treatment well for a final concentration of 10 µmol/L. After 1 hour at 37°C, cells were washed three times with cold PBS and analyzed for FL-2 flourescence on a FACScan machine. Ten-thousand events were recorded for each condition, which were performed in triplicate. Experiments were repeated twice. Antibodies and phenotypic analysis of cell lines.   Cell surface integrin expression was determined using the monoclonal antibodies (MoAbs) P4G9 (DAKO, Carpinteria, CA) for CDw49d (4) analysis, A1A5 for CD29 (1) analysis (T Cell Diagnostics, Woburn, MA), P1D6 (DAKO) for CDw49e (5) analysis, and FIB504 (Pharmingen, San Diego, CA) for 7 analysis. Cells, 1 × 106, were incubated with primary antibody or an isotype control, then with FITC-conjugated goat anti-mouse or goat anti-rat secondary antibody. Fluorescence was then analyzed by flow cytometry with a FACScan machine, which recorded 10,000 events for each experiment. Adhesion assays.   Cells, 1.5 × 105, were adhered to FN- or BSA-coated well plates as described previously. After three washes to remove unattached cells, adherent cells were fixed in 70% methanol for 10 minutes. Following aspiration, wells were allowed to dry and then were stained with 0.02% crystal violet/.2% ethanol for an additional 10 minutes. After solubilization with 100 µL Sorenson buffer, absorbance at 540 nm was read with an automated microtiter plate reader. In some experiments, cells were pre-incubated for 15 minutes with P4G9 or HP2/1 (Clonetech, Palo Alto, CA) (anti-VLA-4), P1D6 (anti-VLA-5), or isotype antibody controls before application to wells.     RESULTS FN-adhered myeloma cells show a decreased response to doxorubicin by MTT cytotoxicity analysis.   To assess whether or not engagement of cell surface integrins can contribute to cell survival, we used a short-term MTT-based cytotoxicity assay. 8226/S cells were adhered to FN-coated wells for 1 hour, and unbound cells were removed by aspiration and washes with serum-free media. As a control, an approximately equal cell number was added to uncoated wells or wells coated with BSA. After 24 hours, doxorubicin or melphalan was added to each well for 1 hour, drug-containing media was then removed and replaced by fresh media. After a 96-hour incubation, cell survival was determined by the ability of viable cells to reduce MTT dye to formazan. IC50 values were derived through linear regression of the log-linear dose-response plots for each cell line to each drug. Student's t-test was used to analyze differences in drug response using data collected from three different experiments (.05 significance level). We found that 8226/S myeloma cells adhered to FN-coated plates have a significant survival advantage over those grown on BSA-coated plates when exposed to doxorubicin for 1 hour following a 24-hour pre-adhesion period (Fig 1A), (n = 3, mean difference = 6.9, SD = 5.2, range = 2.4 to 12.6, P < .05). The mean IC50 value for FN-adhered cells was 1.63 µmol/L dox (SD = 1.51, range = 0.49 µmol/L to 3.34 µmol/L) compared with 0.52 µmol/L for cells grown on BSA (n = 3, SD = 0.76, range = 0.085 µmol/L to 1.4 µmol/L). Subtoxic concentrations of doxorubicin often induced a mitogenic effect in FN-adhered cells (>100% survival), an effect seen with other cell types45 and in drug-resistant cells (our unpublished observations). FN-adhered cells often showed a decreased response to melphalan (Fig 1B); however, this effect proved to be inconsistent (n = 3, mean difference = 1.7, SD = 0.8, range = 1.2 to 2.6). The mean IC50 value for FN-adhered cells was 48 µmol/L melphalan (n = 3, SD = 26 µmol/L, range = 18 µmol/L to 65 µmol/L), compared with 30 µmol/L for cells grown on BSA (n = 3, SD = 20 µmol/L, range = 15 µmol/L to 53 µmol/L). View larger version (10K): [in this window] [in a new window]   Fig 1. 8226/S myeloma cells adhered to FN have a survival advantage over nonadhered cells following acute doxorubicin exposure (A) but not following melphalan exposure (B) in cell growth based cytotoxicity assays. FN-adhered cells (---) were bound to FN-coated plates 24 hours before 1-hour drug exposure and control cells were grown in suspension (). Response to doxorubicin was 12.6-fold lower in FN-adhered cells compared to nonadhered controls (IC50 values for adhered and nonadhered cells were of 4.85 × 107 mol/L and 8.5 × 108 mol/L, respectively). Data points are presented as cell viability determined by MTT cytotoxicity assay compared with untreated controls. Graphs are representative experiments that were repeated three times in replicates of four. Annexin V flow cytometry analysis of apoptosis.   As a second marker for apoptosis not based on cell growth, we used PE- or FITC-conjugated Annexin V, which recognizes inverted phosphatidylserine on the exterior of the plasma membrane as an early stage apoptotic marker. Approximately 0.5 × 106 8226/S cells were adhered to FN-coated or uncoated 6-well tissue culture plates for 24 hours before being exposed to either 1 µmol/L doxorubicin or 50 µmol/L melphalan. After a 24-hour incubation, cells were collected and the apoptotic fraction determined using Annexin V staining and flow cytometric analysis. FN-adhered 8226/S cells had a lower percentage of apoptotic cells (mean = 16.3%) compared with nonadhered controls (mean = 40.3%) following a 1-hour doxorubicin exposure (P < .05) (Fig 2A). A smaller, but statistically different (P < .05), effect was seen with FN-adhered cells treated with 50 µmol/L melphalan (16.53% v 21.5%) (Fig 2B). In some experiments, cells were exposed to drug before FN-adhesion in an attempt to rescue them from the consequent initiation of apoptosis. Annexin V staining revealed that FN adhesion is unable to rescue myeloma cells following initial exposure to doxorubicin or melphalan (data not shown). View larger version (12K): [in this window] [in a new window]   Fig 2. Annexin V stained FN-adhered myeloma cells have a lower apoptotic fraction compared to nonadhered cells following acute drug exposure. 8226/S myeloma cells were exposed to 1 µmol/L doxorubicin for 1 hour (A) or 50 µmol/L melphalan for 24 hours (B), stained by Annexin V 24 hours later, then analyzed by flow cytometry. Histograms are adjusted for background staining in untreated cells, bars are the SD of three different experiments; *, P < .05. Bcl-2, Bcl-XL, Bcl-XS, and BAX mRNA levels are unchanged in 8226/S following 24-hour adhesion to FN.   BCL-2 and BCL-XL are widely known to inhibit the onset of programmed cell death, and others have demonstrated the ability of 1 integrins to upregulate at least one of these genes.14,46 To investigate whether expression of the Bcl-2 family members known to suppress (Bcl-2 and Bcl-XL) or promote (BAX and Bcl-XS) apoptosis were altered in FN-adhered cells, an RNase protection assay was used to observe possible transcriptional changes in these genes. Expression levels and ratios of all Bcl-2 family members were found to be unchanged, and therefore altered RNA levels of these apoptosis regulating proteins are not likely responsible for protecting FN-adhered myeloma cells from acute cytotoxic drug exposure (Fig 3). To confirm these results, semi-quantitative RT-PCR for Bcl-2, Bcl-Xl, Bcl-Xs, and BAX was performed on RNA collected from three different cell samples. As in the RNase protection assay, no significant changes in the levels of these genes were observed in FN-adhered cells. View larger version (48K): [in this window] [in a new window]   Fig 3. RNA levels of Bcl-2 family members are unchanged following FN adhesion. Drug sensitive 8226/S cells were adhered to FN-coated plates or grown in suspension for 24 hours after which total RNA was collected and analyzed by RNase protection. Expression levels were normalized to the housekeeping genes GAPDH and L32. Intracellular doxorubicin accumulation and expression of known drug transporters are not altered by FN adhesion.   Based on the knowledge that active drug transport is a common mechanism of doxorubicin resistance and that in rare instances ECM adhesion can upregulate P-glycoprotein,9 we looked for possible reductions in intracellular drug accumulation in adhered myeloma cells. A flow cytometry-based intracellular drug accumulation assay revealed that the concentration of doxorubicin, which emits at 573 nm after excitation, in FN-adhered myeloma cells is equal to that seen in nonadhered controls (Fig 4). Due to the fact that some drug transporters may alter nuclear drug concentration with minimal effects on total intracellular drug,47 we used RT-PCR to investigate whether three known transport proteins were upregulated by FN adhesion. Two members of the ABC superfamily of transmembrane gycoproteins, MDR1 (encoding P-glycoprotein) and MRP (encoding the multidrug resistance-associated protein), which are known to actively extrude drugs such as doxorubicin, were unchanged following FN adhesion (data not shown). Expression of LRP (lung resistance-associated protein), which has also been associated with drug resistance, was also unchanged in adhered myeloma cells compared with suspension cells (data not shown). In addition to ruling out altered drug transport as a mechanism of adhesion-based drug resistance, these studies also show that ECM components of the bone marrow microenvironment probably do not affect the intrinsic expression of these drug transporters in human myeloma cells. View larger version (10K): [in this window] [in a new window]   Fig 4. Intracellular doxorubicin concentration is unaffected by culturing cells on plastic, BSA, or FN. Following a 24-hour incubation on each surface, 10 µmol/L doxorubicin was added to each well for 1 hour and cells were analyzed for drug accumulation differences by flow cytometry. Bars are the SD of n = 6 from two independent experiments. VLA-4 is overexpressed in drug-resistant variants of the 8226/S myeloma cell line.   Low-level drug-resistant variants were selected from the 8226/S drug-sensitive human myeloma cell line using step-wise increases in melphalan or doxorubicin over a period of approximately 10 months.38,39 The acquired resistance of the 8226/LR5 (L-phenylalanine mustard resistant) cell line is based on the overexpression of glutathione and glutathione-associated enzymes. 8226/DOX6 (doxorubicin resistant) acquired a P-glycoprotein based mechanism of resistance after chronic drug selection. Both of these cell lines were assayed for changes in cell surface integrin expression. Cell lines were incubated with MoAbs to the 4, 5, 1, or 7 integrin subunits, followed by labeling with an FITC-conjugated secondary antibody. In both 8226 cell line variants, acquired resistance to doxorubicin or melphalan was associated with an increase in 4 surface expression as determined by fluorescence activated cell sorting (FACS) analysis (Fig 5, Table 1). When compared with levels found in the 8226/S parent line, 4 subunit expression was increased fourfold in both 8226/LR5 and 8226/DOX6 (n = 3). 1 subunit expression increased 2.5-fold in 8226/LR5 while a more modest increase of 70% was seen in 8226/DOX6 when compared with parent cell line levels. 7 integrin, the only other integrin subunit known to heterodimerize with 4, was increased 3.6-fold in 8226/LR5 but remained unchanged in 8226/DOX6. 5 expression levels remained relatively low in both 8226 drug selected cell lines. View larger version (32K): [in this window] [in a new window]   Fig 5. Phenotypic analysis of 8226 cell surface FN receptor expression by flow cytometry. Integrin subunit expression by drug-sensitive (8226/S), melphalan-resistant (8226/LR5), and doxorubicin-resistant (8226/DOX6) cell lines were analyzed using MoAbs for 4, 5, 1, and 7. Cells were incubated with an integrin-specific MoAb () or with irrelevant control Ab (---), followed by incubation with FITC-conjugated secondary Ab. Ten thousand events were analyzed for each sample using a FACScan machine (Becton-Dickinson); histograms are representative of three different experiments.                                View this table: [in this window] [in a new window]   Table 1. Fluorescence-Activated Cell Sorter Analysis of Integrin Subunits on Drug Sensitive and Drug Resistant Cell Lines Drug sensitive revertant cell lines express 4 levels equal to that of 8226/S.   When removed from drug for a period of 20 weeks, 8226/LR5 reverted back to a drug-sensitive phenotype with 4 integrin expression comparable with the drug sensitive parent cell line 8226 (Fig 6A). The level of 5 remained low in the revertant cell line as well (data not shown). The same observations were made when 8226/DOX6 were removed from maintenance drug for 20 weeks (Fig 6B). These experiments demonstrate a correlation between levels of 4 expression and drug resistance in the 8226 myeloma cell line. Acute exposure of 8226/S to a wide range of concentrations of doxorubicin or melphalan had no immediate effects (1 to 48 hours) on cell surface integrin expression, as determined by FACS analysis (data not shown), suggesting a process of selection for 4 overexpression, rather than drug-induced upregulation of this gene. View larger version (40K): [in this window] [in a new window]   Fig 6. (A) Drug resistance is associated with 4 expression in melphalan-resistant (8226/LR5) and revertant (LR5ood) cell lines. 8226/LR5 were maintained in 5 × 105 mmol/L melphalan (LPAM) and LR5ood were maintained out of drug for 20 weeks. 4 expression was measured by flow cytometry and drug resistance was measured by MTT cytotoxicity analysis. Resistance values are reported as the IC50 dose of LPAM relative to 8226/S. 4 expression levels and melphalan resistance levels of 8226/LR5 were found to be higher than 8226/S (P < .05). 4 expression and melphalan resistance of LR5ood were found to be equal to those of the 8226/S parent line. Bars are the SD of three different experiments. (B) Drug resistance is associated with 4 expression in doxorubicin-resistant (8226/DOX6) and revertant (DOX6ood) cell lines. 8226/DOX6 were maintained in 6 × 108 mol/L doxorubicin and DOX6ood were maintained out of drug for 20 weeks. 4 expression was measured by flow cytometry and drug resistance was measured by MTT cytotoxicity analysis. Resistance values are reported as the IC50 dose of doxorubicin relative to 8226/S. 4 expression levels and doxorubicin resistance levels of 8226/DOX6 were found to be higher than 8226/S (P < .05). 4 expression and doxorubicin resistance of DOX6ood were found to be equal to those of the 8226/S parent line. Bars are the SD of three different experiments. Drug-resistant 8226 cell lines demonstrate increased levels of 4-mediated FN adhesion.   Functionality of surface VLA-4 and VLA-5 was investigated using a fibronectin adhesion assay with precoated microtiter plates. BSA was used to control for nonspecific cell adhesion and several MoAbs were used to inhibit 5 (P1D6)- and 4 (P4G9 and HP2/1)-mediated adhesion. Cell lines selected from 8226/S by continuous drug exposure displayed significant increases in 4-mediated FN binding ability (Fig 7) compared with the parent cell line, 8226/S, which used both 5 and 4 for FN adherence. This class switch of integrins functioning in adherence may be indicative of an advantage in 4- versus 5-mediated signal transduction during the selection process, although further study is needed to investigate these possibilities. View larger version (21K): [in this window] [in a new window]   Fig 7. Contribution of 4 and 5 integrin subunits to FN adhesion. Drug-sensitive (8226/S), melphalan-resistant (8226/LR5), and doxorubicin-resistant (8226/DOX6) were adhered to FN-coated wells (horizontal striped bars) for 1 hour. In order to determine percentage binding due to 4 and 5, some cells were pre-incubated with 4 function blocking Ab P4G9 (hatched bars) or 5 function blocking Ab P1D6 (vertical striped bars) for 15 minutes before application to wells. FN adhesion by 8226/S was found to be mediated equally by 4 and 5, while FN adhesion for both drug-resistant cell lines was mediated only by 4 (P < .05), as determined by complete inhibition of adherence using the 4 blocking Ab. Total FN adhesion mediated by 4 was also higher in drug-resistant lines compared with drug-sensitive 8226/S (P < .05). Values shown are the percentage of total cells applied to each well corrected for nonspecific adhesion to BSA-coated wells. Bars are the SD of n = 6 from three different experiments.     DISCUSSION Classically, investigations of drug resistance have focused on the single cell by selecting for drug resistant cells following exposure to cytotoxic agents. By and large, these studies have revealed mechanisms that reduce intracellular drug concentration (P-glycoprotein, MRP, LRP), detoxify the drug itself (changes in glutathione and glutathione-associated enzymes) or alter the drug target (alterations in topoisomerase II). However, both preclinical and clinical studies indicate that these mechanisms are unlikely to determine initial drug response. It is clear that integrins and ECM interactions play critical roles in cell survival. The evidence presented here suggests that during the course of initial or chronic drug exposure, myeloma cells overexpressing VLA-4 may have a selection advantage over cells expressing low levels of this protein. Experiments involving the treatment of 8226/S with short term (1 to 48 hours) doses of doxorubicin or melphalan indicate that increases in 4 expression are not seen immediately, probably ruling out drug-induced transcriptional upregulation as a reason for FN receptor overexpression. Drug-resistant cells removed from chronic drug exposure eventually lose their high 4 expression levels along with their resistant phenotype, implicating selection pressure as a prerequisite for 4 upregulation. This correlation between integrin expression and resistance levels was seen in both doxorubicin- and melphalan-selected variants of 8226/S. There have been previous links observed between cytotoxic drug exposure and integrin expression and function involving other tumor cell types.48,49 Scotlandi et al and Nista et al also showed integrin upregulation in multidrug resistant osteosarcoma and breast cancer cells, respectively.50,51 Although most of these studies focused on metastatic changes in tumor cells, they do indicate that the effects of common DNA damaging agents on integrin expression and function may not be limited to malignant plasma cells. We have demonstrated, through two distinct apoptosis assays, that cells in direct contact with immobilized FN are less sensitive to acute doxorubicin treatment. A decreased response to melphalan in FN-adhered cells was not consistently observed during acute exposure using MTT cytotoxicity analysis (possibly as a result of assay insensitivity); however, significant increases in cell survival were detected using Annexin V. Although the level of cytoprotection may be small following an acute survival assay, these differences may be sufficient to give rise to a large phenotypically distinct population over the course of chronic drug exposure in vitro or in vivo (a hypothesis currently under investigation in our laboratory). It is not entirely clear whether physical cellular adhesion and spreading is required for integrin-mediated signal transduction. Bozzo et al demonstrated that soluble ECM components applied to suspension cells can activate 1 integrin signaling and suppress apoptosis in the absence of cell adhesion and spreading.46 By this reasoning, soluble FN may have the capacity to induce 1 signaling without adhesion within myeloma cell cultures. The overexpression and use of 4 for FN adhesion by drug-resistant myeloma cell lines may indicate a consequent increase in the number of intercellular interactions (through FN binding, VCAM-1 binding, or homotypic 4 binding52) by tumor cells exposed to DNA damaging agents, or the increased binding of soluble FN from serum. It has been shown that many cultured myeloma cell lines, including 8226, produce a relatively high amount of cell surface FN compared with normal plasma cells, an observation also seen clinically in patient specimens.53,54 DNA damaging agents such as doxorubicin or melphalan may also induce increased production of ligand, as was shown with human mesangial cell cultures and FN synthesis.55 Cells under selection pressure may then use soluble or cell-bound integrin ligands, and subsequent 4-mediated signaling, as a cytoprotective mechanism. Some previously established mechanisms of drug resistance were investigated as possible causes of the cytoprotective effect of FN seen in our assays. Since drug transporters such as P-glycoprotein have been well documented mediators of drug resistance in myeloma cells, we investigated possible alterations in intracellular drug concentration following adhesion. FN-adhered cells were found to contain doxorubicin levels equal to those seen in nonadhered cells using standard techniques. In some cases, intracellular drug compartmentalization can be altered by P-glycoprotein without high levels of drug extrusion,47 for this reason the expression of three drug transporters was analyzed by semi-quantitative RT-PCR.44,56 The expression of MDR1, MRP, and LRP were all equal between FN-adhered and nonadhered cells, probably ruling out induction of active drug transport as a possible mechanism of cytoprotection in these experiments. Another family of proteins known to effect apoptosis and drug response is the Bcl-2 family. VLA-5 and VLA-6 are known, in certain cell types, to upregulate Bcl-2 and protect against apoptosis following ligation with FN or laminin, respectively. RNase protection and RT-PCR assays showed the RNA levels coding for this protein to be unchanged in FN-adhered cells. Furthermore, expression levels of the anti-apoptotic protein Bcl-XL, which is upregulated in keratinocytes following adhesion,57 were unchanged following FN adhesion. No changes in the expression of other anti-apoptotic (Bcl-w and Mcl-1) or pro-apoptotic genes (BAX, Bcl-XS, Bad, and Bik) were detected by either of these assays. However, until further investigation, we cannot rule out the possibility that integrins affect posttranslational modification of these proteins and their potential participation in CAM-DR. Several investigations have put new found significance on the effects of adhesion on cell cycle kinetics and how this may impart drug resistance on tumor cells.8 VLA-4-mediated adhesion is known to decrease the proliferation of hematopoietic progenitor cells58 and the 4 over-expressing cell lines 8226/LR5 and 8226/DOX6 have longer doubling times in culture compared with the 8226/S parent cell line (LR5 = 30 hours, DOX6 = 39 hours, S = 27 hours), (Bellamy et al,39 and unpublished findings, February 1997). Further studies are required before a kinetic mechanism of altered drug response can be implicated in playing a role in FN-mediated cytoprotection. Many recent reports have implicated the phosphatidylinositol 3 kinase (PI3 kinase)/AKT pathway as having a major influence on cellular apoptotic commitment and PI3 kinase activation is a known inhibitor of apoptosis in hematopoietic cells.59-62 Future studies will focus on this pathway as a likely mechanism of apoptotic suppression in FN-adhered cells. Although FN adhesion and VLA-4 ligation is known to initiate the PI3 kinase signaling cascade in some cases, VLA-4 or VLA-5 have not yet been directly correlated with this pathway in myeloma cells.63 Furthermore, a frequent association has been observed between these integrins and FAK, a known activator of PI3 kinase.32,64-66 Through activation by PI3-K lipid products or by direct phosphorylation, AKT is known to phosphorylate the Bcl-XL/Bcl-2-associated death promoter (BAD), promoting cell survival possibly by dissociating it from Bcl-XL and decreasing the amount of BAX homodimers.61 The endpoint of the PI3-K/AKT signaling cascade probably involves an eventual blockade of ced3/ICE activity and a subsequent inhibition of tumor cell death, as has been reported in some cases of cell-ECM interactions.59,67 In summary, we have found a link between integrin-mediated FN adhesion and decreased response to chemotherapeutic drugs as well as a correlation between the expression of 4 integrin heterodimers and drug resistance. We have used the term "cell adhesion-mediated drug resistance," or CAM-DR, to describe this observation. Although the intracellular mechanisms mediating this survival signal are as yet unknown, two well-established causes of drug resistance, active drug transport and increased expression of Bcl-2 family members, have been ruled out. Clinically, elevated FN receptor expression or function in myeloma cells within the bone marrow may be an indicator of a more aggressive tumor cell that has a survival advantage against the cytotoxic effects of anti-cancer drugs. In vivo alterations in fibronectin receptor expression or function may have a magnified effect on myeloma cell survival when they are in direct association with stromal cells and ECM components of the bone marrow. The cytoprotection conferred by fibronectin receptors may be low level, but intrinsic, since most myeloma cells inherently express moderate to high levels of these integrins. Small changes in drug sensitivity in vitro are probably highly relevant clinically since even a 1% surviving tumor fraction can have drastic long-term consequences. The CAM-DR mediated by FN adhesion may be sufficient to allow the eventual emergence of drug resistance mechanisms such as upregulation of P-glycoprotein, MRP, and alterations in topoisomerase II, which then become the predominant cytoprotective processes. Once their role in myeloma is firmly established, specific integrin subunits and the various signal transduction elements they use, may prove to be promising therapeutic targets. Established antagonists of VLA-4 and VLA-5 integrin function may serve as chemosensitizers when administered in conjunction with conventional chemotherapeutics, possibly leading to higher levels of drug response and improved clinical outcome.     ACKNOWLEDGMENT We thank Ibrahim Buyuksal for his help in performing the RNase protection assays, and Marc Oshiro for his help in the PCR assays.     FOOTNOTES Submitted July 14, 1998; accepted October 21, 1998. Supported in part by CA 17094 (WSD). The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. Address reprint requests to William S. Dalton, PhD, MD, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL 33612; e-mail: dalton{at}Moffitt.usf.edu.     REFERENCES Top Abstract Introduction References 1. Schustik C, Dalton WS, Gros P: P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulation, in: Molecular Aspects of Medicine, vol 16. London, UK, Elsevier Science, 1995, p 1. 2. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE: Immunohistochemical detection and quantification of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation. Blood 73:747, 1989[Abstract/Free Full Text] 3. Durand RE, Sutherland RM: Effects of intercellular contact on repair of radiation damage. Exp Cell Res 71:75, 1972[Medline] [Order article via Infotrieve] 4. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei E III: Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247:1457, 1990[Abstract/Free Full Text] 5. Meredeth JE, Fazeli B, Schwartz MA: The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953, 1993[Abstract] 6. Bates RC, Buret A, van Helden DF, Horton MA, Burns GF: Apoptosis induced by inhibition of intercellular contact. J Cell Biol 125:403, 1994[Abstract/Free Full Text] 7. Frisch SM, Hunter F: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619, 1994[Abstract/Free Full Text] 8. St. Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS: Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anticancer agents. Nature Med 2:1204, 1996[Medline] [Order article via Infotrieve] 9. Schuetz JD, Schuetz EG: Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Diff 4:31, 1993[Abstract] 10. Dedhar S: Integrin mediated signal transduction in oncogenesis: An overview. Cancer Metas Rev 14:55, 1996 11. Juliano R: Signal transduction by integrins and its role in the regulation of tumor growth: Cancer Metas Rev 13:25, 1994[Medline] [Order article via Infotrieve] 12. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268:233, 1995[Abstract/Free Full Text] 13. Higashimoto I, Chihara J, Kakazu T, Kawabata M, Nakajima S, Osame M: Regulation of eosinophil cell death by adhesion to fibronectin. Int Arch Allergy Immunol 111:66, 1996 (Suppl 1) 14. Zhang Z, Vuori K, Reed JC, Rouslahti E: The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92:6161, 1995[Abstract/Free Full Text] 15. Scott G, Cassidy L, Busacco A: Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol 108:147, 1997[Medline] [Order article via Infotrieve] 16. Rozzo C, Chiesa C, Caridi G, Pagnan G, Ponzoni M: Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer 70:688, 1997[Medline] [Order article via Infotrieve] 17. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS: Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 56:2146, 1996 18. Fuks Z, Vlodavsky I, Andreeff M, McLoughlin M, Haimovitz-Friedman A: Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer 28A:725, 1992 19. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11, 1992[Medline] [Order article via Infotrieve] 20. Jensen GS, Belch AR, Mant MJ, Ruether BA, Tacyshyn BR, Pilarsky LM: Expression of multiple 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 43:29, 1993[Medline] [Order article via Infotrieve] 21. Barker HF, Ball J, Drew M, Hamilton MS, Franklin IM: The role of adhesion molecules in multiple myeloma. Leuk Lymph 8:189, 1992[Medline] [Order article via Infotrieve] 22. Pulido R, Elices MJ, Campanero MR, Osborn L, Schiffer S, Garcia-Pardo A, Lobb R, Hemler ME, Sanchez-Madrid F: Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. J Biol Chem 266:10241, 1991[Abstract/Free Full Text] 23. Elices MJ, Osborn L, Takada Y, Crouse C, Lujowskyj S, Hemler ME, Lobb RR: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577, 1990[Medline] [Order article via Infotrieve] 24. Anwar ARF, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ: Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 177:839, 1993[Abstract/Free Full Text] 25. Wang MW-J, Consoli U, Lane CM, Durett A, Lauppe MJ, Champlin R, Andreeff M, Deisseroth AB: Rescue from apoptosis in early (CD34-selected) versus late (non-CD-34-selected) human hematopoietic cells by very later antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Diff 9:105, 1998[Abstract] 26. Koopman G, Keehen RMJ, Lindhout E, Newman W, Shimizu Y, van Seventer GA, de Groot C, Pals ST: Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 152:3760, 1994[Abstract] 27. Saiki I, Yoneda J, Kobayashi H, Igarashi Y, Komazawa H, Ishizaki Y, Kato I, Azuma I: Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs. Jpn J Cancer Res 84:326, 1993[Medline] [Order article via Infotrieve] 28. Caligaris-Cappio F, Gregoretti MG, Merico F, Gorrardi D, Ghia P, Parvis G, Bergui L: Bone marrow microenvironment and the progression of multiple myeloma. Leuk Lymph 8:15, 1992[Medline] [Order article via Infotrieve] 29. Bataille R, Chappard D, Klein B: The critical role of IL-6 and macrophage colony stimulating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Clin Lab Res 21:283, 1992[Medline] [Order article via Infotrieve] 30. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma cell lines to bone marrow stromal cells stimulates IL-6 secretion. Blood 82:3712, 1993[Abstract/Free Full Text] 31. Xiao J, Messinger Y, Jin J, Myers DE, Bolen JB, Uckun FM: Signal transduction through the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases. J Biol Chem 271:7659, 1996[Abstract/Free Full Text] 32. Nojima Y, Tachibana K, Sato T, Sclossman SF, Morimoto C: Focal adhesion kinase (pp125FAK) is tyrosine phosphorylated after engagement of 41 and 51 integrins on human t-lymphoblastic cells. Cell Immunol 161:8, 1995[Medline] [Order article via Infotrieve] 33. Zachary I, Rozengurt E: Focal adhesion kinase (p125FAK): A point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell 71:891, 1992[Medline] [Order article via Infotrieve] 34. Chen H-C, Guan J-L: Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 91:10148, 1994[Abstract/Free Full Text] 35. Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619, 1994 36. Hungerford JE, Compton MT, Matter ML, Hoffstrom BG, Otey CA: Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 135:1383, 1996[Abstract/Free Full Text] 37. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD: Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 272:26056, 1997[Abstract/Free Full Text] 38. Dalton WS, Durie BGM, Alberts DS, Gerlach JH, Cress AE: Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:2125, 1986 39. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM: Development and characterization of a melphalan resistant human multiple myeloma cell line. Cancer Res 51:995, 1991[Abstract/Free Full Text] 40. Tu Y, Xu F, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A: Upregulated expression of Bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88:1805, 1996[Abstract/Free Full Text] 41. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS: Quantitative polymerase chain reaction analysis of MDR1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 213:414, 1993[Medline] [Order article via Infotrieve] 42. Benito A, Silver M, Grillot D, Nunez G, Fernandez-Luna JL: Apoptosis induced by erytheroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood 87:3837, 1996[Abstract/Free Full Text] 43. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS: Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematapoietic cells. Cancer Res 54:4676, 1994[Abstract/Free Full Text] 44. Komarov P, Shtil A, Holian O, Tee L, Buckingham L, Mechetner E, Roninson I, Coon J: Activation of the LRP (lung resistance-associated protein) gene by short-term exposure of human leukemia cells to phorbol ester and cytarabine. Oncology Res 10:185, 1998[Medline] [Order article via Infotrieve] 45. Vichi P, Tritton TR: Stimulation of growth in human and murine cells by adriamycin. Cancer Res 49:2679, 1989[Abstract/Free Full Text] 46. Bozzo C, Bellomo G, Silengo L, Tarone G, Altruda F: Soluble integrin ligands and growth factors independently rescue neuroblastoma cells from apoptosis under nonadherent conditions. Exp Cell Res 237:326, 1997[Medline] [Order article via Infotrieve] 47. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS: Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensisitzers. Cancer Res 56:5435, 1996[Abstract/Free Full Text] 48. Duensing S, Brevis Nunez F, Meyer N, Anastassiou G, Nasarek A, Grosse J, Buer J, Probst M, Ganser A, Alzpodien J: Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. Invasion Met 16:65, 1996 49. Sedlak J, Sedlakova O, Hlavcak P, Hunakova L, Bizik J, Grofova M, Chorvath B: Cell surface phenotype and increased penetration of human multidrug-resistant ovarian carcinoma cells into in vitro collagen-fibroblasts matrix. Neoplasma 43:389, 1996[Medline] [Order article via Infotrieve] 50. Scotlandi K, Serra M, Nicoletti G, Vaccari M, Cristina Manara M, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacii M, Baldini N: Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56:2434, 1996[Abstract/Free Full Text] 51. Nista A, Leonetti C, Bernardini G, Mattoni M, Santoni A: Functional role of a4b1 and a5b1 integrin fibronectin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. Int J Cancer 72:133, 1997[Medline] [Order article via Infotrieve] 52. Altevogt P, Hubbe M, Ruppert M, Lohr J, Von Hoegen P, Sammar M, Andrew DP, McEvoy L, Humphries MJ, Butcher EC: The 4 integrin chain is a ligand for 47 and 41. J Exp Med 182:345, 1995[Abstract/Free Full Text] 53. Van Riet I, De Greef C, Del Favero H, Demanet C, Van Camp B: Production of fibronectin and adherence to fibronectin by human myeloma cell lines. Br J Hematol 87:258, 1994[Medline] [Order article via Infotrieve] 54. Paizi M, Manaster J, Quitt M, Spira G: High plasma fibronectin levels in multiple myeloma patients: Possible mechanism and clinical implications. Scand J Immunol 34:285, 1991[Medline] [Order article via Infotrieve] 55. Soose M, Wenzel S, Padur A, Oberst D, Stolte H: Fibronectin expression in human mesangial cell cultures and its alteration by adriamycin. Cell Biol Toxicol 11:51, 1995[Medline] [Order article via Infotrieve] 56. Dalton WS: Detection of multidrug resistance gene expression in multiple myeloma. Leukemia 11:1166, 1997[Medline] [Order article via Infotrieve] 57. Rodeck U, Jost M, DuHadaway J, Kari C, Jensen PJ, Risse B, Ewert DL: Regulation of Bcl-xl expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Proc Natl Acad Sci USA 94:5067, 1997[Abstract/Free Full Text] 58. Hurley RW, McCarthy JB, Verfaillie CM: Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 96:511, 1995 59. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Devel 11:701, 1997[Abstract/Free Full Text] 60. Marte BM, Downward J: PKB/Akt: Connecting phophonisositide 3-kinase to cell survival and beyond. TIBS 22:355, 1997 61. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 92:231, 1997 62. Scheid MP, Lauener RW, Duronio V: Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: Phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J 312:159, 1995 63. Ricard I, Payet MD, Dupuis G: Clustering the adhesion molecules VLA-4 (CD49d/CD29) in jurkat T cells or VCAM-1 (CD106) in endothelial (ECV 304) cells activates the phosphoinositide pathway and triggers Ca2+ mobilization. Eur J Immunol 27:1530, 1997[Medline] [Order article via Infotrieve] 64. King WG, Mattaliano MD, Chan TO, Tsichlis RN, Brugge JS: Phosphatidylinositol 3-kinase is required for integrin stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 17:4406, 1997[Abstract] 65. Morimoto C, Iwata S, Tachibana K: VLA-4-mediated signaling. Curr Opin Micro Immunol 231:1, 1998 66. Chen Q, Kinch MS, Lin TH, Burridge K, Juliano RL: Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J Biol Chem 269:26602, 1994[Abstract/Free Full Text] 67. Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891, 1995[Abstract/Free Full Text] © 1999 by The American Society of Hematology.   0006-4971/99/9305-0006$3.00/0 CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. V. Kurtova, K. Balakrishnan, R. Chen, W. Ding, S. Schnabl, M. P. Quiroga, M. Sivina, W. G. Wierda, Z. Estrov, M. J. Keating, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance Blood, November 12, 2009; 114(20): 4441 - 4450. [Abstract] [Full Text] [PDF] J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio The microenvironment in mature B-cell malignancies: a target for new treatment strategies Blood, October 15, 2009; 114(16): 3367 - 3375. [Abstract] [Full Text] [PDF] L. Krasny, N. Shimony, K. Tzukert, R. Gorodetsky, S. Lecht, D. M. Nettelbeck, and Y. S. Haviv An in-vitro tumour microenvironment model using adhesion to type I collagen reveals Akt-dependent radiation resistance in renal cancer cells Nephrol. Dial. Transplant., October 13, 2009; (2009) gfp525v1. [Abstract] [Full Text] [PDF] R. R. Nair, M. F. Emmons, A. E. Cress, R. F. Argilagos, K. Lam, W. T. Kerr, H.-G. Wang, W. S. Dalton, and L. A. Hazlehurst HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells Mol. Cancer Ther., August 1, 2009; 8(8): 2441 - 2451. [Abstract] [Full Text] [PDF] A. K. Azab, F. Azab, S. Blotta, C. M. Pitsillides, B. Thompson, J. M. Runnels, A. M. Roccaro, H. T. Ngo, M. R. Melhem, A. Sacco, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma Blood, July 16, 2009; 114(3): 619 - 629. [Abstract] [Full Text] [PDF] H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al. The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Clin. Cancer Res., June 15, 2009; 15(12): 4028 - 4037. [Abstract] [Full Text] [PDF] B. Nervi, P. Ramirez, M. P. Rettig, G. L. Uy, M. S. Holt, J. K. Ritchey, J. L. Prior, D. Piwnica-Worms, G. Bridger, T. J. Ley, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 Blood, June 11, 2009; 113(24): 6206 - 6214. [Abstract] [Full Text] [PDF] M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood, May 28, 2009; 113(22): 5549 - 5557. [Abstract] [Full Text] [PDF] A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting Blood, May 7, 2009; 113(19): 4604 - 4613. [Abstract] [Full Text] [PDF] A. K. Azab, J. M. Runnels, C. Pitsillides, A.-S. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, B. Ospina, A. L. Carlson, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Blood, April 30, 2009; 113(18): 4341 - 4351. [Abstract] [Full Text] [PDF] J. C. Puigvert, S. Huveneers, L. Fredriksson, M. o. h. Veld, B. van de Water, and E. H. J. Danen Cross-Talk between Integrins and Oncogenes Modulates Chemosensitivity Mol. Pharmacol., April 1, 2009; 75(4): 947 - 955. [Abstract] [Full Text] [PDF] T. M. Tancred, A. R. Belch, T. Reiman, L. M. Pilarski, and J. Kirshner Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance J. Histochem. Cytochem., March 1, 2009; 57(3): 239 - 247. [Abstract] [Full Text] [PDF] K. H. Shain, D. N. Yarde, M. B. Meads, M. Huang, R. Jove, L. A. Hazlehurst, and W. S. Dalton {beta}1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation Cancer Res., February 1, 2009; 69(3): 1009 - 1015. [Abstract] [Full Text] [PDF] Y. Okawa, T. Hideshima, P. Steed, S. Vallet, S. Hall, K. Huang, J. Rice, A. Barabasz, B. Foley, H. Ikeda, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK Blood, January 22, 2009; 113(4): 846 - 855. [Abstract] [Full Text] [PDF] T. Ara, L. Song, H. Shimada, N. Keshelava, H. V. Russell, L. S. Metelitsa, S. G. Groshen, R. C. Seeger, and Y. A. DeClerck Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells Cancer Res., January 1, 2009; 69(1): 329 - 337. [Abstract] [Full Text] [PDF] E. David, R. Sinha, J. Chen, S.-Y. Sun, J. L. Kaufman, and S. Lonial Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors Clin. Cancer Res., August 15, 2008; 14(16): 5090 - 5098. [Abstract] [Full Text] [PDF] C. C. Park, H. J. Zhang, E. S. Yao, C. J. Park, and M. J. Bissell {beta}1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts Cancer Res., June 1, 2008; 68(11): 4398 - 4405. [Abstract] [Full Text] [PDF] M. B. Meads, L. A. Hazlehurst, and W. S. Dalton The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance Clin. Cancer Res., May 1, 2008; 14(9): 2519 - 2526. [Abstract] [Full Text] [PDF] A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al. Thalidomide for treatment of multiple myeloma: 10 years later Blood, April 15, 2008; 111(8): 3968 - 3977. [Abstract] [Full Text] [PDF] Y. Nefedova, D. M. Sullivan, S. C. Bolick, W. S. Dalton, and D. I. Gabrilovich Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy Blood, February 15, 2008; 111(4): 2220 - 2229. [Abstract] [Full Text] [PDF] L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP J. Immunol., February 1, 2008; 180(3): 1545 - 1555. [Abstract] [Full Text] [PDF] S. T. Pals, D. J. J. de Gorter, and M. Spaargaren Lymphoma dissemination: the other face of lymphocyte homing Blood, November 1, 2007; 110(9): 3102 - 3111. [Abstract] [Full Text] [PDF] J. C. Friedland, J. N. Lakins, M. G. Kazanietz, J. Chernoff, D. Boettiger, and V. M. Weaver {alpha}6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-{kappa}B-dependent resistance to apoptosis in 3D mammary acini J. Cell Sci., October 15, 2007; 120(20): 3700 - 3712. [Abstract] [Full Text] [PDF] T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells Blood, July 15, 2007; 110(2): 709 - 718. [Abstract] [Full Text] [PDF] T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells Mol. Cancer Ther., June 1, 2007; 6(6): 1718 - 1727. [Abstract] [Full Text] [PDF] M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism Mol. Cancer Ther., June 1, 2007; 6(6): 1774 - 1784. [Abstract] [Full Text] [PDF] N. J. Bahlis, A. M. King, D. Kolonias, L. M. Carlson, H. Y. Liu, M. A. Hussein, H. R. Terebelo, G. E. Byrne Jr, B. L. Levine, L. H. Boise, et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival Blood, June 1, 2007; 109(11): 5002 - 5010. [Abstract] [Full Text] [PDF] S. M. Pupa, S. Giuffre, F. Castiglioni, L. Bertola, M. Cantu, I. Bongarzone, P. Baldassari, R. Mortarini, W. S. Argraves, A. Anichini, et al. Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1 Cancer Res., May 1, 2007; 67(9): 4271 - 4277. [Abstract] [Full Text] [PDF] G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib Blood, April 15, 2007; 109(8): 3177 - 3188. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF] W. Dalton and K. C. Anderson Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6603 - 6610. [Abstract] [Full Text] [PDF] L. Catley, E. Weisberg, T. Kiziltepe, Y.-T. Tai, T. Hideshima, P. Neri, P. Tassone, P. Atadja, D. Chauhan, N. C. Munshi, et al. Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood, November 15, 2006; 108(10): 3441 - 3449. [Abstract] [Full Text] [PDF] T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al. MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clin. Cancer Res., October 1, 2006; 12(19): 5887 - 5894. [Abstract] [Full Text] [PDF] M. Li, S. Cortez, T. Nakamachi, V. Batuman, and A. Arimura Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells. Cancer Res., September 1, 2006; 66(17): 8796 - 8803. [Abstract] [Full Text] [PDF] M. A. Hussein, R. Baz, G. Srkalovic, N. Agrawal, R. Suppiah, E. Hsi, S. Andresen, M. A. Karam, J. Reed, B. Faiman, et al. Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma Mayo Clin. Proc., July 1, 2006; 81(7): 889 - 895. [Abstract] [Full Text] [PDF] B. Hoang, L. Zhu, Y. Shi, P. Frost, H. Yan, S. Sharma, S. Sharma, L. Goodglick, S. Dubinett, and A. Lichtenstein Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance Blood, June 1, 2006; 107(11): 4484 - 4490. [Abstract] [Full Text] [PDF] T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF] G. Bisping, M. Kropff, D. Wenning, B. Dreyer, S. Bessonov, F. Hilberg, G. J. Roth, G. Munzert, M. Stefanic, M. Stelljes, et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups Blood, March 1, 2006; 107(5): 2079 - 2089. [Abstract] [Full Text] [PDF] J. A. Burger and T. J. Kipps CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment Blood, March 1, 2006; 107(5): 1761 - 1767. [Abstract] [Full Text] [PDF] L. A. Hazlehurst, R. F. Argilagos, M. Emmons, D. Boulware, C. A. Beam, D. M. Sullivan, and W. S. Dalton Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells Cancer Res., February 15, 2006; 66(4): 2338 - 2345. [Abstract] [Full Text] [PDF] L. Drucker, T. Tohami, S. Tartakover-Matalon, V. Zismanov, H. Shapiro, J. Radnay, and M. Lishner Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines Carcinogenesis, February 1, 2006; 27(2): 197 - 204. [Abstract] [Full Text] [PDF] N. Yanamandra, N. M. Colaco, N. A. Parquet, R. W. Buzzeo, D. Boulware, G. Wright, L. E. Perez, W. S. Dalton, and D. M. Beaupre Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia Clin. Cancer Res., January 15, 2006; 12(2): 591 - 599. [Abstract] [Full Text] [PDF] G. S. Nowakowski, T. E. Witzig, D. Dingli, M. J. Tracz, M. A. Gertz, M. Q. Lacy, J. A. Lust, A. Dispenzieri, P. R. Greipp, R. A. Kyle, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma Blood, October 1, 2005; 106(7): 2276 - 2279. [Abstract] [Full Text] [PDF] G. Saunders Overview of drug therapy for multiple myeloma Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100. [Abstract] [PDF] K. Ishitsuka, T. Hideshima, M. Hamasaki, N. Raje, S. Kumar, H. Hideshima, N. Shiraishi, H. Yasui, A. M. Roccaro, P. Richardson, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis Blood, September 1, 2005; 106(5): 1794 - 1800. [Abstract] [Full Text] [PDF] M. Burger, T. Hartmann, M. Krome, J. Rawluk, H. Tamamura, N. Fujii, T. J. Kipps, and J. A. Burger Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells Blood, September 1, 2005; 106(5): 1824 - 1830. [Abstract] [Full Text] [PDF] H. Yasui, T. Hideshima, N. Raje, A. M. Roccaro, N. Shiraishi, S. Kumar, M. Hamasaki, K. Ishitsuka, Y.-T. Tai, K. Podar, et al. FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance Cancer Res., August 15, 2005; 65(16): 7478 - 7484. [Abstract] [Full Text] [PDF] N. Raje, S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. Munshi, S. R. Green, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Blood, August 1, 2005; 106(3): 1042 - 1047. [Abstract] [Full Text] [PDF] Q. Chen, P. C. Van der Sluis, D. Boulware, L. A. Hazlehurst, and W. S. Dalton The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells Blood, July 15, 2005; 106(2): 698 - 705. [Abstract] [Full Text] [PDF] H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma Blood, July 15, 2005; 106(2): 706 - 712. [Abstract] [Full Text] [PDF] X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells Clin. Cancer Res., June 15, 2005; 11(12): 4589 - 4600. [Abstract] [Full Text] [PDF] M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo Blood, June 1, 2005; 105(11): 4470 - 4476. [Abstract] [Full Text] [PDF] M. S. Duxbury, H. Ito, E. Benoit, T. Waseem, S. W. Ashley, and E. E. Whang RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresistance Clin. Cancer Res., May 1, 2005; 11(9): 3433 - 3438. [Abstract] [Full Text] [PDF] K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF] T. Matsumoto and M. Abe The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions IBMS BoneKEy, February 1, 2005; 2(2): 7 - 10. [Full Text] [PDF] N. W.C.J. van de Donk, H. M. Lokhorst, E. H.J. Nijhuis, M. M.J. Kamphuis, and A. C. Bloem Geranylgeranylated Proteins are Involved in the Regulation of Myeloma Cell Growth Clin. Cancer Res., January 15, 2005; 11(2): 429 - 439. [Abstract] [Full Text] [PDF] D. L. Olson, L. C. Burkly, D. R. Leone, B. M. Dolinski, and R. R. Lobb Anti-{alpha}4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model Mol. Cancer Ther., January 1, 2005; 4(1): 91 - 99. [Abstract] [Full Text] [PDF] T. Hayashi, T. Hideshima, A. N. Nguyen, O. Munoz, K. Podar, M. Hamasaki, K. Ishitsuka, H. Yasui, P. Richardson, S. Chakravarty, et al. Transforming Growth Factor {beta} Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment Clin. Cancer Res., November 15, 2004; 10(22): 7540 - 7546. [Abstract] [Full Text] [PDF] D. Chauhan, G. Li, K. Podar, T. Hideshima, C. Mitsiades, R. Schlossman, N. Munshi, P. Richardson, F. E. Cotter, and K. C. Anderson Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells Blood, October 15, 2004; 104(8): 2458 - 2466. [Abstract] [Full Text] [PDF] M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF] T. Kurita-Ochiai, S. Seto, and K. Ochiai Role of Cell-Cell Communication in Inhibiting Butyric Acid-Induced T-Cell Apoptosis Infect. Immun., October 1, 2004; 72(10): 5947 - 5954. [Abstract] [Full Text] [PDF] R. Schmidmaier, P. Baumann, M. Simsek, F. Dayyani, B. Emmerich, and G. Meinhardt The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase Blood, September 15, 2004; 104(6): 1825 - 1832. [Abstract] [Full Text] [PDF] C. N. Papandreou and C. J. Logothetis Bortezomib as a Potential Treatment for Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5036 - 5043. [Abstract] [Full Text] [PDF] T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF] E. Petitclerc, R. G. Deschesnes, M.-F. Cote, C. Marquis, R. Janvier, J. Lacroix, E. Miot-Noirault, J. Legault, E. Mounetou, J.-C. Madelmont, et al. Antiangiogenic and Antitumoral Activity of Phenyl-3-(2-Chloroethyl)Ureas: A Class of Soft Alkylating Agents Disrupting Microtubules That Are Unaffected by Cell Adhesion-Mediated Drug Resistance Cancer Res., July 1, 2004; 64(13): 4654 - 4663. [Abstract] [Full Text] [PDF] C. Recher, L. Ysebaert, O. Beyne-Rauzy, V. Mansat-De Mas, J.-B. Ruidavets, P. Cariven, C. Demur, B. Payrastre, G. Laurent, and C. Racaud-Sultan Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis Cancer Res., May 1, 2004; 64(9): 3191 - 3197. [Abstract] [Full Text] [PDF] M. Alsina, R. Fonseca, E. F. Wilson, A. N. Belle, E. Gerbino, T. Price-Troska, R. M. Overton, G. Ahmann, L. M. Bruzek, A. A. Adjei, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma Blood, May 1, 2004; 103(9): 3271 - 3277. [Abstract] [Full Text] [PDF] Y. Nefedova, P. Cheng, M. Alsina, W. S. Dalton, and D. I. Gabrilovich Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines Blood, May 1, 2004; 103(9): 3503 - 3510. [Abstract] [Full Text] [PDF] D. Chauhan, G. Li, K. Podar, T. Hideshima, R. Shringarpure, L. Catley, C. Mitsiades, N. Munshi, Y. T. Tai, N. Suh, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance Blood, April 15, 2004; 103(8): 3158 - 3166. [Abstract] [Full Text] [PDF] Y. Dai, X.-Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant Interruption of the NF-{kappa}B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells Blood, April 1, 2004; 103(7): 2761 - 2770. [Abstract] [Full Text] [PDF] S. K. Green, G. Francia, C. Isidoro, and R. S. Kerbel Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro Mol. Cancer Ther., February 1, 2004; 3(2): 149 - 159. [Abstract] [Full Text] [PDF] M. Fornaro, J. Plescia, S. Chheang, G. Tallini, Y.-M. Zhu, M. King, D. C. Altieri, and L. R. Languino Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-{alpha}-induced Apoptosis via the AKT/Survivin Pathway J. Biol. Chem., December 12, 2003; 278(50): 50402 - 50411. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al. Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma Cancer Res., December 1, 2003; 63(23): 8428 - 8436. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454. [Abstract] [Full Text] [PDF] L. A. Hazlehurst, S. A. Enkemann, C. A. Beam, R. F. Argilagos, J. Painter, K. H. Shain, S. Saporta, D. Boulware, L. Moscinski, M. Alsina, et al. Genotypic and Phenotypic Comparisons of de Novo and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model Cancer Res., November 15, 2003; 63(22): 7900 - 7906. [Abstract] [Full Text] [PDF] H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis J. Clin. Oncol., November 15, 2003; 21(22): 4239 - 4247. [Abstract] [Full Text] [PDF] C. S. Mitsiades, N. S. Mitsiades, R. T. Bronson, D. Chauhan, N. Munshi, S. P. Treon, C. A. Maxwell, L. Pilarski, T. Hideshima, R. M. Hoffman, et al. Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in Vivo Model: Biologic and Clinical Implications Cancer Res., October 15, 2003; 63(20): 6689 - 6696. [Abstract] [Full Text] [PDF] P. A. Croonquist, M. A. Linden, F. Zhao, and B. G. Van Ness Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells Blood, October 1, 2003; 102(7): 2581 - 2592. [Abstract] [Full Text] [PDF] Y.-T. Tai, K. Podar, L. Catley, Y.-H. Tseng, M. Akiyama, R. Shringarpure, R. Burger, T. Hideshima, D. Chauhan, N. Mitsiades, et al. Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of {beta}1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling Cancer Res., September 15, 2003; 63(18): 5850 - 5858. [Abstract] [Full Text] [PDF] D. Chauhan, G. Li, D. Auclair, T. Hideshima, P. Richardson, K. Podar, N. Mitsiades, C. Mitsiades, C. Li, R. S. Kim, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays Blood, May 1, 2003; 101(9): 3606 - 3614. [Abstract] [Full Text] [PDF] N. Mitsiades, C. S. Mitsiades, P. G. Richardson, V. Poulaki, Y.-T. Tai, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood, March 15, 2003; 101(6): 2377 - 2380. [Abstract] [Full Text] [PDF] M. Filipits, G. Pohl, T. Stranzl, H. Kaufmann, J. Ackermann, H. Gisslinger, H. Greinix, A. Chott, and J. Drach Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma Clin. Cancer Res., February 1, 2003; 9(2): 820 - 826. [Abstract] [Full Text] [PDF] N. J. Bahlis, J. McCafferty-Grad, I. Jordan-McMurry, J. Neil, I. Reis, M. Kharfan-Dabaja, J. Eckman, M. Goodman, H. F. Fernandez, L. H. Boise, et al. Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma Clin. Cancer Res., December 1, 2002; 8(12): 3658 - 3668. [Abstract] [Full Text] [PDF] K. C. Anderson and W. S. Dalton Synopsis of a Research Roundtable Presented on Cell Signaling in Myeloma: Regulation of Growth and Apoptosis--Opportunities for New Drug Discovery Mol. Cancer Ther., December 1, 2002; 1(14): 1361 - 1365. [Abstract] [Full Text] [PDF] I. Gojo, B. Zhang, and R. G. Fenton The Cyclin-dependent Kinase Inhibitor Flavopiridol Induces Apoptosis in Multiple Myeloma Cells through Transcriptional Repression and Down-Regulation of Mcl-1 Clin. Cancer Res., November 1, 2002; 8(11): 3527 - 3538. [Abstract] [Full Text] [PDF] Y. Dai, T. H. Landowski, S. T. Rosen, P. Dent, and S. Grant Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism Blood, October 16, 2002; 100(9): 3333 - 3343. [Abstract] [Full Text] [PDF] B. Lin, K. Podar, D. Gupta, Y.-T. Tai, S. Li, E. Weller, T. Hideshima, S. Lentzsch, F. Davies, C. Li, et al. The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment Cancer Res., September 1, 2002; 62(17): 5019 - 5026. [Abstract] [Full Text] [PDF] D. Chauhan, L. Catley, T. Hideshima, G. Li, R. Leblanc, D. Gupta, M. Sattler, P. Richardson, R. L. Schlossman, K. Podar, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells Blood, August 28, 2002; 100(6): 2187 - 2194. [Abstract] [Full Text] [PDF] T. Hayashi, T. Hideshima, M. Akiyama, P. Richardson, R. L. Schlossman, D. Chauhan, N. C. Munshi, S. Waxman, and K. C. Anderson Arsenic Trioxide Inhibits Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment Mol. Cancer Ther., August 1, 2002; 1(10): 851 - 860. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, et al. NF-kappa B as a Therapeutic Target in Multiple Myeloma J. Biol. Chem., May 3, 2002; 277(19): 16639 - 16647. [Abstract] [Full Text] [PDF] B. Zhang, I. Gojo, and R. G. Fenton Myeloid cell factor-1 is a critical survival factor for multiple myeloma Blood, March 15, 2002; 99(6): 1885 - 1893. [Abstract] [Full Text] [PDF] M. T. de la Fuente, B. Casanova, J. V. Moyano, M. Garcia-Gila, L. Sanz, J. Garcia-Marco, A. Silva, and A. Garcia-Pardo Engagement of {alpha}4{beta}1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine J. Leukoc. Biol., March 1, 2002; 71(3): 495 - 502. [Abstract] [Full Text] [PDF] K. Podar, Y.-T. Tai, B. K. Lin, R. P. Narsimhan, M. Sattler, T. Kijima, R. Salgia, D. Gupta, D. Chauhan, and K. C. Anderson Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with beta 1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCalpha Activation J. Biol. Chem., March 1, 2002; 277(10): 7875 - 7881. [Abstract] [Full Text] [PDF] K. H. Shain, T. H. Landowski, and W. S. Dalton Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines J. Immunol., March 1, 2002; 168(5): 2544 - 2553. [Abstract] [Full Text] [PDF] N. Tsukada, J. A. Burger, N. J. Zvaifler, and T. J. Kipps Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia Blood, February 1, 2002; 99(3): 1030 - 1037. [Abstract] [Full Text] [PDF] K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text] G. S. Watts, B. W. Futscher, R. Isett, M. Gleason-Guzman, M. W. Kunkel, and S. E. Salmon cDNA Microarray Analysis of Multidrug Resistance: Doxorubicin Selection Produces Multiple Defects in Apoptosis Signaling Pathways J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 434 - 441. [Abstract] [Full Text] [PDF] K. H. Shain and W. S. Dalton Cell Adhesion Is a Key Determinant in de Novo Multidrug Resistance (MDR): New Targets for the Prevention of Acquired MDR Mol. Cancer Ther., November 1, 2001; 1(1): 69 - 78. [Abstract] [Full Text] [PDF] L. A. Hazlehurst, N. Valkov, L. Wisner, J. A. Storey, D. Boulware, D. M. Sullivan, and W. S. Dalton Reduction in drug-induced DNA double-strand breaks associated with {beta}1 integrin-mediated adhesion correlates with drug resistance in U937 cells Blood, September 15, 2001; 98(6): 1897 - 1903. [Abstract] [Full Text] [PDF] G. Laurent and J.-P. Jaffrezou Signaling pathways activated by daunorubicin Blood, August 15, 2001; 98(4): 913 - 924. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Damiano, J. S. Articles by Dalton, W. S. Search for Related Content PubMed PubMed Citation Articles by Damiano, J. S. Articles by Dalton, W. S. Related Collections Neoplasia Social Bookmarking                   What's this?

	Copyright © 1999 by American Society of Hematology         Online ISSN: 1528-0020